Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NovoTTF-100A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Best Standard of Care | ACTIVE_COMPARATOR | Patients randomized to the BSC group will be treated with one chemotherapy according to the BSC practiced at each center. |
| NovoTTF-100A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NovoTTF-100A | DEVICE | multiple four-week courses of continuous NovoTTF-100A treatment |
Inclusion Criteria: * Pathological evidence of GBM using WHO classification criteria. * \> 18 years of age. * Not a candidate for further radiotherapy or additional resection of residual tumor. * Patients with disease progression (by Macdonald criteria i.e., \> 25% or new lesion) documented by CT o...
NovoTTF-100A is used for the treatment of recurrent glioblastoma multiforme (GBM), a type of brain cancer. It is an investigational device being studied in patients whose glioblastoma has returned after prior treatment. The device is intended to deliver tumor treating fields to slow or stop cancer cell growth.
NovoTTF-100A is developed by NovoCure Limited, a company publicly traded under the ticker symbol NVCR. NovoCure is an oncology company focused on developing tumor treating fields therapy for solid tumors, including glioblastoma multiforme.
NovoTTF-100A is in Phase 3 clinical development for recurrent glioblastoma multiforme. It is an investigational device and has not been approved by regulatory authorities. A Phase 3 trial has been completed to evaluate its safety and efficacy in this patient population.
NovoTTF-100A has been studied in a completed Phase 3 clinical trial identified as NCT00379470, titled "Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)." The trial enrolled 236 participants across multiple countries, including the United States, Austria, Czechia, France, Germany, Israel, and Switzerland.
NovoTTF-100A is a device that delivers tumor treating fields, a form of low-intensity electric fields, to the brain. These fields are designed to disrupt cancer cell division and interfere with tumor growth. The device is applied to the scalp and is intended to be worn continuously by patients.